FibroBiologics, Inc. Retained Earnings
FibroBiologics, Inc. (FBLG) had Retained Earnings of -$63.28 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-31
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$63.28M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$59.16M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$54.16M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$50.92M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$63.28M 10-Q · filed 2026-07-31 |
| 2026-03-31 | -$59.16M 10-Q · filed 2026-04-30 |
| 2025-12-31 | -$54.16M 10-Q · filed 2026-07-31 |
| 2025-09-30 | -$50.92M 10-Q · filed 2025-10-31 |
| 2025-06-30 | -$45.14M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$40.48M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$35.52M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$32.42M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$31.92M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$32.82M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$24.36M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$7.87M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |